{"nctId":"NCT00567567","briefTitle":"Comparing Two Different Myeloablation Therapies in Treating Young Patients Who Are Undergoing a Stem Cell Transplant for High-Risk Neuroblastoma","startDateStruct":{"date":"2007-11-05","type":"ACTUAL"},"conditions":["Localized Resectable Neuroblastoma","Localized Unresectable Neuroblastoma","Recurrent Neuroblastoma","Regional Neuroblastoma","Stage 4 Neuroblastoma","Stage 4S Neuroblastoma"],"count":665,"armGroups":[{"label":"Consolidation Arm A: single myeloablative consolidation","type":"ACTIVE_COMPARATOR","interventionNames":["Procedure: Autologous Hematopoietic Stem Cell Transplantation","Drug: Carboplatin","Drug: Cisplatin","Drug: Cyclophosphamide","Drug: Doxorubicin Hydrochloride","Drug: Etoposide","Radiation: External Beam Radiation Therapy","Biological: Filgrastim","Drug: Isotretinoin","Other: Laboratory Biomarker Analysis","Drug: Melphalan","Procedure: Peripheral Blood Stem Cell Transplantation","Other: Pharmacological Study","Drug: Topotecan Hydrochloride","Drug: Vincristine Sulfate Liposome"]},{"label":"Consolidation Arm B: tandem myeloablative consolidation","type":"EXPERIMENTAL","interventionNames":["Procedure: Autologous Hematopoietic Stem Cell Transplantation","Drug: Carboplatin","Drug: Cisplatin","Drug: Cyclophosphamide","Drug: Doxorubicin Hydrochloride","Drug: Etoposide","Radiation: External Beam Radiation Therapy","Biological: Filgrastim","Drug: Isotretinoin","Other: Laboratory Biomarker Analysis","Drug: Melphalan","Procedure: Peripheral Blood Stem Cell Transplantation","Other: Pharmacological Study","Drug: Thiotepa","Drug: Topotecan Hydrochloride","Drug: Vincristine Sulfate Liposome"]}],"interventions":[{"name":"Autologous Hematopoietic Stem Cell Transplantation","otherNames":["Autologous Hematopoietic Cell Transplantation","autologous stem cell transplantation"]},{"name":"Carboplatin","otherNames":["Blastocarb","Carboplat","Carboplatin Hexal","Carboplatino","Carbosin","Carbosol","Carbotec","CBDCA","Displata","Ercar","JM-8","Nealorin","Novoplatinum","Paraplatin","Paraplatin AQ","Paraplatine","Platinwas","Ribocarbo"]},{"name":"Cisplatin","otherNames":["Abiplatin","Blastolem","Briplatin","CDDP","Cis-diammine-dichloroplatinum","Cis-diamminedichloridoplatinum","Cis-diamminedichloro Platinum (II)","Cis-diamminedichloroplatinum","Cis-dichloroammine Platinum (II)","Cis-platinous Diamine Dichloride","Cis-platinum","Cis-platinum II","Cis-platinum II Diamine Dichloride","Cismaplat","Cisplatina","Cisplatinum","Cisplatyl","Citoplatino","Citosin","Cysplatyna","DDP","Lederplatin","Metaplatin","Neoplatin","Peyrone's Chloride","Peyrone's Salt","Placis","Plastistil","Platamine","Platiblastin","Platiblastin-S","Platinex","Platinol","Platinol- AQ","Platinol-AQ","Platinol-AQ VHA Plus","Platinoxan","Platinum","Platinum Diamminodichloride","Platiran","Platistin","Platosin"]},{"name":"Cyclophosphamide","otherNames":["(-)-Cyclophosphamide","2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate","Carloxan","Ciclofosfamida","Ciclofosfamide","Cicloxal","Clafen","Claphene","CP monohydrate","CTX","CYCLO-cell","Cycloblastin","Cycloblastine","Cyclophospham","Cyclophosphamid monohydrate","Cyclophosphamidum","Cyclophosphan","Cyclophosphane","Cyclophosphanum","Cyclostin","Cyclostine","Cytophosphan","Cytophosphane","Cytoxan","Fosfaseron","Genoxal","Genuxal","Ledoxina","Mitoxan","Neosar","Revimmune","Syklofosfamid","WR- 138719"]},{"name":"Doxorubicin Hydrochloride","otherNames":["5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8, 9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, hydrochloride, (8S-cis)- (9CI)","ADM","Adriacin","Adriamycin","Adriamycin Hydrochloride","Adriamycin PFS","Adriamycin RDF","ADRIAMYCIN, HYDROCHLORIDE","Adriamycine","Adriblastina","Adriblastine","Adrimedac","Chloridrato de Doxorrubicina","DOX","DOXO-CELL","Doxolem","Doxorubicin.HCl","Doxorubin","Farmiblastina","FI 106","FI-106","hydroxydaunorubicin","Rubex"]},{"name":"Etoposide","otherNames":["Demethyl Epipodophyllotoxin Ethylidine Glucoside","EPEG","Lastet","Toposar","Vepesid","VP 16-213","VP-16","VP-16-213"]},{"name":"External Beam Radiation Therapy","otherNames":["Definitive Radiation Therapy","EBRT","External Beam Radiotherapy","External Beam RT","external radiation","External Radiation Therapy","external-beam radiation"]},{"name":"Filgrastim","otherNames":["FILGRASTIM, LICENSE HOLDER UNSPECIFIED","G-CSF","Neupogen","r-metHuG-CSF","Recombinant Methionyl Human Granulocyte Colony Stimulating Factor","rG-CSF","Tevagrastim"]},{"name":"Isotretinoin","otherNames":["13-cis retinoic acid","13-cis-Retinoate","13-cis-Retinoic Acid","13-cis-Vitamin A Acid","13-cRA","Accure","Accutane","Amnesteem","cis-Retinoic Acid","Cistane","Claravis","Isotretinoinum","Isotrex","Isotrexin","Neovitamin A","Neovitamin A Acid","Oratane","Retinoicacid-13-cis","Ro 4-3780","Ro-4-3780","Roaccutan","Roaccutane","Roacutan","Sotret"]},{"name":"Laboratory Biomarker Analysis","otherNames":[]},{"name":"Melphalan","otherNames":["Alanine Nitrogen Mustard","CB-3025","L-PAM","L-Phenylalanine Mustard","L-sarcolysin","L-Sarcolysin Phenylalanine mustard","L-Sarcolysine","Melphalanum","Phenylalanine Mustard","Phenylalanine nitrogen mustard","Sarcoclorin","Sarkolysin","WR-19813"]},{"name":"Peripheral Blood Stem Cell Transplantation","otherNames":["PBPC transplantation","PBSCT","Peripheral Blood Progenitor Cell Transplantation","Peripheral Stem Cell Support","Peripheral Stem Cell Transplant","Peripheral Stem Cell Transplantation"]},{"name":"Pharmacological Study","otherNames":[]},{"name":"Thiotepa","otherNames":["1,1',1''-Phosphinothioylidynetrisaziridine","Girostan","N,N', N''-Triethylenethiophosphoramide","Oncotiotepa","STEPA","Tepadina","TESPA","Tespamin","Tespamine","Thio-Tepa","Thiofosfamide","Thiofozil","Thiophosphamide","Thiophosphoramide","Thiotef","Tifosyl","TIO TEF","Tio-tef","Triethylene thiophosphoramide","Triethylenethiophosphoramide","Tris(1-aziridinyl)phosphine sulfide","TSPA","WR 45312"]},{"name":"Topotecan Hydrochloride","otherNames":["Hycamptamine","Hycamtin","SKF S-104864-A","Topotecan HCl","topotecan hydrochloride (oral)"]},{"name":"Vincristine Sulfate Liposome","otherNames":["Marqibo"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Diagnosis of neuroblastoma or ganglioneuroblastoma by histology or as evidenced by the presence of clumps of tumor cells in bone marrow and elevated catecholamine metabolites in urine meeting any of the following criteria:\n\n  * Patients with newly diagnosed neuroblastoma with International Neuroblastoma Staging System (INSS) stage 4 disease are eligible with the following:\n\n    * MYCN amplification (i.e., greater than four-fold increase in MYCN signals as compared to reference signals), regardless of age or additional biologic features\n    * Age \\> 18 months (i.e., \\> 547 days) regardless of biologic features\n    * Age 12-18 months (i.e., 365-547 days) with none of the following three favorable biologic features (i.e., non-amplified MYCN, favorable pathology, and deoxyribonucleic acid \\[DNA\\] index \\> 1)\n  * Patients with newly diagnosed neuroblastoma with INSS stage 3 are eligible with the following:\n\n    * MYCN amplification (i.e., greater than four-fold increase in MYCN signals as compared to reference signals), regardless of age or additional biologic features\n    * Age \\> 18 months (i.e., \\> 547 days) with unfavorable pathology, regardless of MYCN status\n  * Patients with newly diagnosed INSS stage 2a or 2b with MYCN amplification (i.e., greater than four-fold increase in MYCN signals as compared to reference signals), regardless of age or additional biologic features\n  * Patients with newly diagnosed INSS stage 4s with MYCN amplification (i.e., greater than four-fold increase in MYCN signals as compared to reference signals), regardless of additional biologic features\n  * Patients \\>= 365 days initially diagnosed with INSS stage 1, 2, or 4S and who progressed to a stage 4 without interval chemotherapy\n\n    * Must have been enrolled on COG-ANBL00B1\n* Creatinine clearance or radioisotope glomerular filtration rate ? 70mL/min OR serum creatinine based on age/gender as follows:\n\n  * 1 month to \\< 6 months: 0.4 mg/dL\n  * 6 months to \\< 1 year: 0.5 mg/dL\n  * 1 to \\< 2 years: 0.6 mg/dL\n  * 2 to \\< 6 years: 0.8 mg/dL\n  * 6 to \\< 10 years: 1 mg/dL\n  * 10 to \\< 13 years: 1.2 mg/dL\n  * 10 to \\< 16 years: 1.5 mg/dL (male), 1.4 mg/dL (female)\n  * \\>= 16 years: 1.7 mg/dL (male), 1.4 mg/dL (female)\n* Total bilirubin ? 1.5 times upper limit of normal (ULN) for age\n* Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) \\< 10 times ULN for age\n* Not pregnant or nursing\n* Negative pregnancy test\n* Shortening fraction \\>= 27% by echocardiogram (ECHO) OR left ventricular ejection fraction (LVEF) \\>= 50% by radionuclide angiogram\n* No known contraindication (e.g., size, weight or physical condition) to peripheral blood stem cell collection\n* No prior systemic therapy except for localized emergency radiation to sites of life-threatening or function-threatening disease\n* No more than one course of chemotherapy per low- or intermediate-risk neuroblastoma therapy prior to determination of MYCN amplification and histology","healthyVolunteers":false,"sex":"ALL","maximumAge":"30 Years","stdAges":["CHILD","ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Event-free Survival Rate","description":"Comparison of EFS curves, starting from the time of randomization, by treatment group (single CEM vs. tandem CEM)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"48.8","spread":null},{"groupId":"OG001","value":"61.8","spread":null}]}]}]},{"type":"PRIMARY","title":"Response After Induction Therapy","description":"Per the International Response Criteria: measurable tumor defined as product of longest x widest perpendicular diameter. Elevated catecholamine levels, tumor cell invasion of bone marrow also considered measurable tumor. Complete Response (CR)-no evidence of primary tumor or metastases. Very Good Partial Response (VGPR)-\\>90% reduction of primary tumor; no metastases; no new bone lesions, all pre-existing lesions improved. Partial Response (PR)-50-90% reduction of primary tumor; \\>50% reduction in measurable sites of metastases; 0-1 bone marrow samples with tumor; number of positive bone sites decreased by \\>50%. Mixed Response (MR)-\\>50% reduction of any measurable lesion (primary or metastases) with \\<50% reduction in other sites; no new lesions; \\<25% increase in any existing lesion. No Response (NR)-no new lesions; \\<50% reduction but \\<25% increase in any existing legions. Progressive Disease (PD)-any new/increased measurable lesion by \\>25%; previous negative marrow positive.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.54","spread":null},{"groupId":"OG001","value":"0.48","spread":null},{"groupId":"OG002","value":"0.35","spread":null}]}]}]},{"type":"PRIMARY","title":"Incidence Rate of Local Recurrence","description":"Cumulative incidence rate of local recurrence comparison between ANBL0532 patients randomized or assigned to receive single CEM transplant and boost radiation versus the historical A3973 patients who were transplanted and received boost radiation.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Duration of Greater Than or Equal to Grade 3 Neutropenia","description":"A logistic regression model will be used to test the ability of the number of days of neutropenia to predict the presence of a polymorphism.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"7","spread":null},{"groupId":"OG002","value":"7","spread":null}]}]}]},{"type":"SECONDARY","title":"Duration of Greater Than or Equal to Grade 3 Thrombocytopenia","description":"A logistic regression model will be used to test the ability of the number of days of thrombocytopenia to predict the presence of a polymorphism.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"4","spread":null},{"groupId":"OG002","value":"4","spread":null}]}]}]},{"type":"SECONDARY","title":"Proportion of Patients With a Polymorphism","description":"A chi-square test will be used to test whether the response rate after two cycles of induction therapy and the presence of a polymorphism are independent in the study population.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.96","spread":null},{"groupId":"OG001","value":"0.96","spread":null},{"groupId":"OG002","value":"0.97","spread":null}]}]}]},{"type":"SECONDARY","title":"Surgical Response","description":"Percentage of patients who achieved a surgical complete resection","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"83.98","spread":null},{"groupId":"OG001","value":"84.09","spread":null},{"groupId":"OG002","value":"58.89","spread":null}]}]}]},{"type":"SECONDARY","title":"Type of Surgical or Radiotherapy Complication","description":"The Percentage of patients who experienced surgical or radiotherapy complications will be calculated. The complications are: bowel obstruction, chylous leaf, renal injury/atrophy/loss and diarrhea.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13.11","spread":null},{"groupId":"OG001","value":"12.50","spread":null},{"groupId":"OG002","value":"11.85","spread":null}]}]}]},{"type":"SECONDARY","title":"Intraspinal Extension","description":"Percentage of patients with primary tumors with intraspinal extension.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.25","spread":null},{"groupId":"OG001","value":"9.66","spread":null},{"groupId":"OG002","value":"7.78","spread":null}]}]}]},{"type":"SECONDARY","title":"Peak Serum Concentration of Isotretinoin in Patients Enrolled on Either A3973, ANBL0032, ANBL0931, ANBL0532 and Future High Risk Studies","description":"Median peak serum concentration level of isotretinoin for patients enrolled on ANBL0532","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.00","spread":null},{"groupId":"OG001","value":"1.36","spread":null},{"groupId":"OG002","value":"1.26","spread":null}]}]}]},{"type":"SECONDARY","title":"Pharmacogenetic Variants in Patients Enrolled on Either A3973, ANBL0032, ANBL0931, ANBL0532 and Future High Risk Studies","description":"To determine if pharmacogenomic variations are predictive of EFS, a logrank test comparison of patients with vs without a given polymorphism will be made. A Fisher's exact test will test for association of the presence of a polymorphism with the occurrence of systemic toxicity (CTC grade 3 or 4 skin, hypercalcemia, or hepatic toxicity). These tests will be performed for UGT1A1, UGT2B7, CYP2C8 and CYP3A7 alleles.","classes":[]},{"type":"SECONDARY","title":"Topotecan Systemic Clearance","description":"Median topotecan systemic clearance for courses 1 and 2.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"28.1","spread":null},{"groupId":"OG001","value":"28.1","spread":null},{"groupId":"OG002","value":"28.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Presence and Function of T Cells Capable of Recognizing Neuroblastoma","description":null,"classes":[]},{"type":"SECONDARY","title":"Enumeration of Peripheral Blood Cluster of Differentiation (CD)3, CD4, and CD8 Cells","description":"A descriptive comparison of the median number of T-cells (CD3, CD4, CD8) between treatment arms (single vs. tandem myeloablative regimens) will be performed.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"200","spread":null},{"groupId":"OG001","value":"255.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"73","spread":null},{"groupId":"OG001","value":"81","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"104","spread":null},{"groupId":"OG001","value":"151","spread":null}]}]}]},{"type":"SECONDARY","title":"Proportion of Patients With Neuroblastoma Detected in Bone Marrow and Peripheral Blood Using RT-PCR Technique","description":"Will be calculated overall and by treatment arm.","classes":[]},{"type":"SECONDARY","title":"EFS Pts Non-randomly Assigned to Single CEM (12-18 Mths, Stg. 4, MYCN Nonamplified Tumor/Unfavorable or Indeterminant Histopathology/Diploid DNA Content & Pts>547 Days, Stg.3, MYCN Nonamplified Tumor AND Unfavorable or Indeterminant Histopathology).","description":"Kaplan-Meier curves of EFS will be plotted, and the proportion of responders to induction therapy will be tabulated.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"73.1","spread":null}]}]}]},{"type":"SECONDARY","title":"OS in Patients 12-18 Months, Stage 4, MYCN Nonamplified Tumor/Unfavorable Histopathology/Diploid DNA Content/Indeterminant Histology/Ploidy and Patients > 547 Days, Stage 3, MYCN Nonamplified Tumor AND Unfavorable Histopathology/Indeterminant Histology","description":"Kaplan-Meier curves of OS will be plotted, and the proportion of responders to induction therapy will be tabulated.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"81.0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":16,"n":206},"commonTop":["58300-Neutrophil count decreased","65800-Platelet count decreased","33300-Febrile neutropenia","44800-Infections and infestations - Other specify","88500-White blood cell decreased"]}}}